Stockwatch: Drug reimbursement Elysium?
This article was originally published in Scrip
In the 2013 science fiction film Elysium the human race was divided up into the wealthy, who lived on the utopian space station Elysium with access to the machines that could cure all injuries and diseases, and those who were stuck with poverty and disease back on a dystopian polluted earth. After last week's American College of Cardiology (ACC) conference, we may be a little closer to this sort of bifurcation in healthcare.
You may also be interested in...
The impact of the coronavirus pandemic on investors’ portfolios was immediately apparent at the end of the first quarter of 2020. Equity market sell-offs are reflections of investors’ concern for future financial performance which, if material, may have to be announced early.
AbbVie’s latest, largest acquisition may be cast in a new light as the pandemic throws stock markets into turmoil and commercial prospects up in the air.
The prices of biotechnology and pharmaceutical sector indices continue to be comparatively robust in the face of big falls in global markets as investors expect new drugs and vaccines to be generated by the sector. While it is largely accepted that the life science sector will eventually ride to the rescue, bumper profits are far from guaranteed.